ROCKVILLE, Md.--(BUSINESS WIRE)--BioMarker Strategies, LLC, today announced the appointment of Samuel Broder, M.D., as Chairman of its Scientific Advisory Board and his election as a member of the Company’s Board of Directors, effective immediately.
“We are privileged to bring a leader of Dr. Broder’s distinction and scientific experience back to our Company. His record of accomplishment in internal medicine and oncology are well known, and we look forward to benefiting from his scientific and strategic insight in the years ahead,” said Jerry Parrott, President and CEO, BioMarker Strategies. “I am particularly pleased that Dr. Broder has agreed to take on the important role of Chairman of our Scientific Advisory Board. We expect to announce the members of our newly constituted SAB in the near future.”
“I am quite familiar with the BioMarker Strategies SnapPath® cancer diagnostics system and its capacity to profile key functional biomarkers through the ex vivo exposure of live solid tumor cells to targeted treatments,” said Dr. Broder. “This approach can provide direct information regarding responses of the dynamic signaling pathways of living tumor cells to targeted therapies. It has the potential to substantially improve our ability to predict which targeted treatment or combination is most likely to provide therapeutic benefit to individual patients.”
Dr. Broder, former Director of the National Cancer Institute, previously served on the BioMarker Strategies Board and left it in 2012 to accept a position with Intrexon Corporation. Intrexon subsequently went public in 2013 (NYSE: XON). He served as Director of the NCI for six years, and before he became Director, Dr, Broder’s laboratory at NCI was instrumental in developing several of the first drugs now widely used in the treatment of AIDS, as well as a number of very important anticancer agents.
Dr. Broder also served as Executive Vice President and Chief Medical Officer at Celera for 12 years, as Chairman of the Health Section and Executive Vice President of Scientific and Public Affairs at Intrexon, and as Senior Vice President of Research and Development at IVAX Corporation, which was acquired by Teva Pharmaceutical Industries Ltd., in 2005. Dr. Broder holds multiple patents, a number of which have resulted in commercialized products. He is a member of the Institute of Medicine of the National Academy of Sciences, and has authored or co-authored more than 340 scholarly papers. He received his bachelor’s and M.D. degrees from the University of Michigan.
About BioMarker Strategies
BioMarker Strategies has developed SnapPath®, the only cancer diagnostics system that automates and standardizes functional ex vivo profiling of live solid tumor cells from fresh biopsies or other fresh, unfixed samples such as xenografts or tumorgrafts. SnapPath® can help guide cancer drug development and treatment selection. The Company’s PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatment. PathMAP® Melanoma is currently in development as a companion diagnostic under a National Cancer Institute SBIR Phase II contract, the ultimate goal of which is to prepare for a clinical trial of PathMAP® Melanoma under a Phase IIB NCI contract. Patents for SnapPath® have been allowed and are proceeding to grant in Europe and Australia, and applications are pending in the U.S. and other countries. Patents for PathMAP® Functional Signaling Profiles have been allowed and are proceeding to grant in Australia and Singapore, and applications are pending in Europe, the U.S. and other countries. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.
The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.